Abiopharma

🔍 Lu Peng (Executive)

Company: Pharvaris N.V. (PHVS)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 15,000 shares of Common Stock at $2.59 per share (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: false | shares_owned_after: 80,631.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 11,600 shares of Common Stock at $34.4547 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: false | shares_owned_after: 69,031.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,400 shares of Common Stock at $35.0913 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: false | shares_owned_after: 65,631.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 14,700 shares of Common Stock at $2.59 per share (Direct)
  Date: 2026-06-26 | Code: M | equity_swap_involved: false | shares_owned_after: 80,331.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 14,700 shares of Common Stock at $34.0032 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: false | shares_owned_after: 65,631.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 15,000 shares of Stock Option (Right to Buy) at $2.59 per share (Derivative)
  Date: 2026-06-25 | Code: M | Expires: 2030-02-03 | equity_swap_involved: false | shares_owned_after: 190,008.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 14,700 shares of Stock Option (Right to Buy) at $2.59 per share (Derivative)
  Date: 2026-06-26 | Code: M | Expires: 2030-02-03 | equity_swap_involved: false | shares_owned_after: 175,308.00 | transaction_form_type: 4 | Footnotes: F1, F5

Footnotes:

• F1: This is a scheduled exercise and sale from 10b5-1 trading plan.
• F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to $34.98. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F3: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F4: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to 34.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F5: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.